Fusobacterium nucleatum facilitates ulcerative colitis through activating IL‐17F signaling to NF‐κB via the upregulation of CARD3 expression

Yongyu Chen,Yan Chen,Pan Cao,Wenhao Su,Na Zhan,Weiguo Dong
DOI: https://doi.org/10.1002/path.5358
2019-12-02
The Journal of Pathology
Abstract:<p>Accumulating evidence links <i>Fusobacterium nucleatum</i> (<i>F. nucleatum</i>) with ulcerative colitis (UC). The mechanism by which <i>F. nucleatum</i> promotes intestinal inflammation in UC remains poorly defined. Here, we first examined the abundance and impact of <i>F. nucleatum</i> on disease activity in UC tissues. Next, we isolated a strain of <i>F. nucleatum</i> from UC tissues and explored whether <i>F. nucleatum</i> aggravates the intestinal inflammatory response <i>in vitro</i> and <i>in vivo</i>. We also examined whether <i>F. nucleatum</i> infection involves the nuclear factor‐κB (NF‐κB) or interleukin (IL)‐17F signaling pathways. Our data showed that <i>F. nucleatum</i> was enriched in 51.78% of UC tissues and was correlated with the clinical course, clinical activity and refractory behavior of UC (<i>P</i> &lt; 0.05). Furthermore, we demonstrated that <i>F. nucleatum</i> promoted intestinal epithelial damage and the expression of the inflammatory cytokines IL‐1β, Il‐6, IL‐17F and TNF‐α. Mechanistically, <i>F. nucleatum</i> targeted CARD3 through NOD2 to activate the IL‐17F/NF‐κB pathway <i>in vivo</i> and <i>in vitro</i>. Thus, <i>F. nucleatum</i> orchestrates a molecular network involving CARD3 and IL‐17F to control the UC process. Measuring and targeting <i>F. nucleatum</i> and its associated pathways will yield valuable insight into the prevention and treatment of UC.</p><p>This article is protected by copyright. All rights reserved.</p>
What problem does this paper attempt to address?